BioSpace News Archive

The poster’s authors include scientists from the laboratories of Professor John Williams of the Beckman Research Institute at the City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University, along with Dr. Margaret Karow, Senior Vice President of Drug Discovery and Preclinical Development at Akriveia Therapeutics.

WIB launched Boardroom Ready in 2016.

ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types.

CB-839 is an orally bioavailable glutaminase inhibitor currently in Phase 2 trials, and Opdivo® is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.

The company intends to host a conference call the same day at 5:00 p.m. ET to discuss the financial results.

A growing number of companies in China are focusing on biopharma, at the same time that global pharmaceutical companies are locating their process development and production in the area.

Auryxia is the only oral treatment option available today developed and approved specifically for adults living with iron deficiency anemia and chronic kidney disease, not on dialysis.

Alvogen is seeking approval to market and sell a generic version of Minivelle (estradiol transdermal system) prior to the expiration of two of Noven’s Orange Book listed patents (U.S. Patent Nos. 9724310 and 9730900).

The filing contains clinical data from the Company’s 864-patient Total PSA clinical study.

The company announced positive new data from both its OLINVOTM (oliceridine injection) and TRV250 programs.